Casimersen for Duchenne muscular dystrophy
This article summarizes the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety.PMID:34909800 | DOI:10.1358/dot.2021.57.12.3352740 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: H Wilton-Clark T Yokota Source Type: research

Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research

Loncastuximab tesirine for diffuse large B-cell lymphoma
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.ABSTRACTLoncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical data demonstrated the selectivity and efficacy of the drug through in vitro and in vivo models. A phase I clinical trial included relapsed, refractory B-cell non-Hodgkin lymphoma (NHL) and demonstrated a tolerable safety profile, with major adverse effects being neutropenia, thromb...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Zurko M Hamadani Source Type: research

Ponesimod to treat multiple sclerosis
Drugs Today (Barc). 2021 Dec;57(12):745-758. doi: 10.1358/dot.2021.57.12.3353166.ABSTRACTPonesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. ...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: A Ianniello C Pozzilli Source Type: research

American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)
Drugs Today (Barc). 2021 Dec;57(12):759-763. doi: 10.1358/dot.2021.57.12.3393255.ABSTRACTACR Convergence is the annual meeting of the American College of Rheumatology (ACR). This year, ACR Convergence was to be held in San Francisco, California, but due to the COVID-19 crisis and subsequent travel restrictions, it was changed to a virtual meeting format. The meeting comprised several days of live sessions and on-demand virtual content including posters and prerecorded presentations.PMID:34909804 | DOI:10.1358/dot.2021.57.12.3393255 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: M Spence Source Type: research

Casimersen for Duchenne muscular dystrophy
This article summarizes the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety.PMID:34909800 | DOI:10.1358/dot.2021.57.12.3352740 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: H Wilton-Clark T Yokota Source Type: research

Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research

Loncastuximab tesirine for diffuse large B-cell lymphoma
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.ABSTRACTLoncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical data demonstrated the selectivity and efficacy of the drug through in vitro and in vivo models. A phase I clinical trial included relapsed, refractory B-cell non-Hodgkin lymphoma (NHL) and demonstrated a tolerable safety profile, with major adverse effects being neutropenia, thromb...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Zurko M Hamadani Source Type: research

Ponesimod to treat multiple sclerosis
Drugs Today (Barc). 2021 Dec;57(12):745-758. doi: 10.1358/dot.2021.57.12.3353166.ABSTRACTPonesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. ...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: A Ianniello C Pozzilli Source Type: research

American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)
Drugs Today (Barc). 2021 Dec;57(12):759-763. doi: 10.1358/dot.2021.57.12.3393255.ABSTRACTACR Convergence is the annual meeting of the American College of Rheumatology (ACR). This year, ACR Convergence was to be held in San Francisco, California, but due to the COVID-19 crisis and subsequent travel restrictions, it was changed to a virtual meeting format. The meeting comprised several days of live sessions and on-demand virtual content including posters and prerecorded presentations.PMID:34909804 | DOI:10.1358/dot.2021.57.12.3393255 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: M Spence Source Type: research

Casimersen for Duchenne muscular dystrophy
This article summarizes the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety.PMID:34909800 | DOI:10.1358/dot.2021.57.12.3352740 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: H Wilton-Clark T Yokota Source Type: research

Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research

Loncastuximab tesirine for diffuse large B-cell lymphoma
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.ABSTRACTLoncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical data demonstrated the selectivity and efficacy of the drug through in vitro and in vivo models. A phase I clinical trial included relapsed, refractory B-cell non-Hodgkin lymphoma (NHL) and demonstrated a tolerable safety profile, with major adverse effects being neutropenia, thromb...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Zurko M Hamadani Source Type: research

Ponesimod to treat multiple sclerosis
Drugs Today (Barc). 2021 Dec;57(12):745-758. doi: 10.1358/dot.2021.57.12.3353166.ABSTRACTPonesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. ...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: A Ianniello C Pozzilli Source Type: research

American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)
Drugs Today (Barc). 2021 Dec;57(12):759-763. doi: 10.1358/dot.2021.57.12.3393255.ABSTRACTACR Convergence is the annual meeting of the American College of Rheumatology (ACR). This year, ACR Convergence was to be held in San Francisco, California, but due to the COVID-19 crisis and subsequent travel restrictions, it was changed to a virtual meeting format. The meeting comprised several days of live sessions and on-demand virtual content including posters and prerecorded presentations.PMID:34909804 | DOI:10.1358/dot.2021.57.12.3393255 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: M Spence Source Type: research

Casimersen for Duchenne muscular dystrophy
This article summarizes the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety.PMID:34909800 | DOI:10.1358/dot.2021.57.12.3352740 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: H Wilton-Clark T Yokota Source Type: research

Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research

Loncastuximab tesirine for diffuse large B-cell lymphoma
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.ABSTRACTLoncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical data demonstrated the selectivity and efficacy of the drug through in vitro and in vivo models. A phase I clinical trial included relapsed, refractory B-cell non-Hodgkin lymphoma (NHL) and demonstrated a tolerable safety profile, with major adverse effects being neutropenia, thromb...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Zurko M Hamadani Source Type: research

Ponesimod to treat multiple sclerosis
Drugs Today (Barc). 2021 Dec;57(12):745-758. doi: 10.1358/dot.2021.57.12.3353166.ABSTRACTPonesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. ...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: A Ianniello C Pozzilli Source Type: research

American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)
Drugs Today (Barc). 2021 Dec;57(12):759-763. doi: 10.1358/dot.2021.57.12.3393255.ABSTRACTACR Convergence is the annual meeting of the American College of Rheumatology (ACR). This year, ACR Convergence was to be held in San Francisco, California, but due to the COVID-19 crisis and subsequent travel restrictions, it was changed to a virtual meeting format. The meeting comprised several days of live sessions and on-demand virtual content including posters and prerecorded presentations.PMID:34909804 | DOI:10.1358/dot.2021.57.12.3393255 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: M Spence Source Type: research

Casimersen for Duchenne muscular dystrophy
This article summarizes the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety.PMID:34909800 | DOI:10.1358/dot.2021.57.12.3352740 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: H Wilton-Clark T Yokota Source Type: research

Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research

Loncastuximab tesirine for diffuse large B-cell lymphoma
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.ABSTRACTLoncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical data demonstrated the selectivity and efficacy of the drug through in vitro and in vivo models. A phase I clinical trial included relapsed, refractory B-cell non-Hodgkin lymphoma (NHL) and demonstrated a tolerable safety profile, with major adverse effects being neutropenia, thromb...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Zurko M Hamadani Source Type: research

Ponesimod to treat multiple sclerosis
Drugs Today (Barc). 2021 Dec;57(12):745-758. doi: 10.1358/dot.2021.57.12.3353166.ABSTRACTPonesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. ...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: A Ianniello C Pozzilli Source Type: research

American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)
Drugs Today (Barc). 2021 Dec;57(12):759-763. doi: 10.1358/dot.2021.57.12.3393255.ABSTRACTACR Convergence is the annual meeting of the American College of Rheumatology (ACR). This year, ACR Convergence was to be held in San Francisco, California, but due to the COVID-19 crisis and subsequent travel restrictions, it was changed to a virtual meeting format. The meeting comprised several days of live sessions and on-demand virtual content including posters and prerecorded presentations.PMID:34909804 | DOI:10.1358/dot.2021.57.12.3393255 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: M Spence Source Type: research

Casimersen for Duchenne muscular dystrophy
This article summarizes the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety.PMID:34909800 | DOI:10.1358/dot.2021.57.12.3352740 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: H Wilton-Clark T Yokota Source Type: research

Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research

Loncastuximab tesirine for diffuse large B-cell lymphoma
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.ABSTRACTLoncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical data demonstrated the selectivity and efficacy of the drug through in vitro and in vivo models. A phase I clinical trial included relapsed, refractory B-cell non-Hodgkin lymphoma (NHL) and demonstrated a tolerable safety profile, with major adverse effects being neutropenia, thromb...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Zurko M Hamadani Source Type: research

Ponesimod to treat multiple sclerosis
Drugs Today (Barc). 2021 Dec;57(12):745-758. doi: 10.1358/dot.2021.57.12.3353166.ABSTRACTPonesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. ...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: A Ianniello C Pozzilli Source Type: research

American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)
Drugs Today (Barc). 2021 Dec;57(12):759-763. doi: 10.1358/dot.2021.57.12.3393255.ABSTRACTACR Convergence is the annual meeting of the American College of Rheumatology (ACR). This year, ACR Convergence was to be held in San Francisco, California, but due to the COVID-19 crisis and subsequent travel restrictions, it was changed to a virtual meeting format. The meeting comprised several days of live sessions and on-demand virtual content including posters and prerecorded presentations.PMID:34909804 | DOI:10.1358/dot.2021.57.12.3393255 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: M Spence Source Type: research

Casimersen for Duchenne muscular dystrophy
This article summarizes the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety.PMID:34909800 | DOI:10.1358/dot.2021.57.12.3352740 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: H Wilton-Clark T Yokota Source Type: research

Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research

Loncastuximab tesirine for diffuse large B-cell lymphoma
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.ABSTRACTLoncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical data demonstrated the selectivity and efficacy of the drug through in vitro and in vivo models. A phase I clinical trial included relapsed, refractory B-cell non-Hodgkin lymphoma (NHL) and demonstrated a tolerable safety profile, with major adverse effects being neutropenia, thromb...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Zurko M Hamadani Source Type: research

Ponesimod to treat multiple sclerosis
Drugs Today (Barc). 2021 Dec;57(12):745-758. doi: 10.1358/dot.2021.57.12.3353166.ABSTRACTPonesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. ...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: A Ianniello C Pozzilli Source Type: research

American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)
Drugs Today (Barc). 2021 Dec;57(12):759-763. doi: 10.1358/dot.2021.57.12.3393255.ABSTRACTACR Convergence is the annual meeting of the American College of Rheumatology (ACR). This year, ACR Convergence was to be held in San Francisco, California, but due to the COVID-19 crisis and subsequent travel restrictions, it was changed to a virtual meeting format. The meeting comprised several days of live sessions and on-demand virtual content including posters and prerecorded presentations.PMID:34909804 | DOI:10.1358/dot.2021.57.12.3393255 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: M Spence Source Type: research

Casimersen for Duchenne muscular dystrophy
This article summarizes the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety.PMID:34909800 | DOI:10.1358/dot.2021.57.12.3352740 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: H Wilton-Clark T Yokota Source Type: research

Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research

Loncastuximab tesirine for diffuse large B-cell lymphoma
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.ABSTRACTLoncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical data demonstrated the selectivity and efficacy of the drug through in vitro and in vivo models. A phase I clinical trial included relapsed, refractory B-cell non-Hodgkin lymphoma (NHL) and demonstrated a tolerable safety profile, with major adverse effects being neutropenia, thromb...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Zurko M Hamadani Source Type: research

Ponesimod to treat multiple sclerosis
Drugs Today (Barc). 2021 Dec;57(12):745-758. doi: 10.1358/dot.2021.57.12.3353166.ABSTRACTPonesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. ...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: A Ianniello C Pozzilli Source Type: research

American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)
Drugs Today (Barc). 2021 Dec;57(12):759-763. doi: 10.1358/dot.2021.57.12.3393255.ABSTRACTACR Convergence is the annual meeting of the American College of Rheumatology (ACR). This year, ACR Convergence was to be held in San Francisco, California, but due to the COVID-19 crisis and subsequent travel restrictions, it was changed to a virtual meeting format. The meeting comprised several days of live sessions and on-demand virtual content including posters and prerecorded presentations.PMID:34909804 | DOI:10.1358/dot.2021.57.12.3393255 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: M Spence Source Type: research

Casimersen for Duchenne muscular dystrophy
This article summarizes the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety.PMID:34909800 | DOI:10.1358/dot.2021.57.12.3352740 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: H Wilton-Clark T Yokota Source Type: research

Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research

Loncastuximab tesirine for diffuse large B-cell lymphoma
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.ABSTRACTLoncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical data demonstrated the selectivity and efficacy of the drug through in vitro and in vivo models. A phase I clinical trial included relapsed, refractory B-cell non-Hodgkin lymphoma (NHL) and demonstrated a tolerable safety profile, with major adverse effects being neutropenia, thromb...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Zurko M Hamadani Source Type: research

Ponesimod to treat multiple sclerosis
Drugs Today (Barc). 2021 Dec;57(12):745-758. doi: 10.1358/dot.2021.57.12.3353166.ABSTRACTPonesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. ...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: A Ianniello C Pozzilli Source Type: research

American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)
Drugs Today (Barc). 2021 Dec;57(12):759-763. doi: 10.1358/dot.2021.57.12.3393255.ABSTRACTACR Convergence is the annual meeting of the American College of Rheumatology (ACR). This year, ACR Convergence was to be held in San Francisco, California, but due to the COVID-19 crisis and subsequent travel restrictions, it was changed to a virtual meeting format. The meeting comprised several days of live sessions and on-demand virtual content including posters and prerecorded presentations.PMID:34909804 | DOI:10.1358/dot.2021.57.12.3393255 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: M Spence Source Type: research

Casimersen for Duchenne muscular dystrophy
This article summarizes the preclinical and clinical data currently available for casimersen, emphasizing pharmacokinetics and safety.PMID:34909800 | DOI:10.1358/dot.2021.57.12.3352740 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: H Wilton-Clark T Yokota Source Type: research

Delgocitinib in atopic dermatitis
Drugs Today (Barc). 2021 Dec;57(12):719-731. doi: 10.1358/dot.2021.57.12.3352760.ABSTRACTDelgocitinib ointment is a newly approved topical medication for the treatment of atopic dermatitis (AD). AD usually has onset in early childhood and is a common, often chronic relapsing inflammatory skin condition that affects all age groups. AD has a large impact on patients' quality of life including physical health and emotional impacts. Conventional management of AD consists of phototherapy and treatments that comprise corticosteroids (both topically and systemically), topical calcineurin inhibitors (tacrolimus and pimecrolimus) o...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Ho S Molin Source Type: research

Loncastuximab tesirine for diffuse large B-cell lymphoma
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.ABSTRACTLoncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate, was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma on the basis of the results of a phase II clinical trial, LOTIS-2. Preclinical data demonstrated the selectivity and efficacy of the drug through in vitro and in vivo models. A phase I clinical trial included relapsed, refractory B-cell non-Hodgkin lymphoma (NHL) and demonstrated a tolerable safety profile, with major adverse effects being neutropenia, thromb...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: J Zurko M Hamadani Source Type: research

Ponesimod to treat multiple sclerosis
Drugs Today (Barc). 2021 Dec;57(12):745-758. doi: 10.1358/dot.2021.57.12.3353166.ABSTRACTPonesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. ...
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: A Ianniello C Pozzilli Source Type: research

American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) 2021 Annual Meeting (November 5-9, 2021 - Virtual Meeting)
Drugs Today (Barc). 2021 Dec;57(12):759-763. doi: 10.1358/dot.2021.57.12.3393255.ABSTRACTACR Convergence is the annual meeting of the American College of Rheumatology (ACR). This year, ACR Convergence was to be held in San Francisco, California, but due to the COVID-19 crisis and subsequent travel restrictions, it was changed to a virtual meeting format. The meeting comprised several days of live sessions and on-demand virtual content including posters and prerecorded presentations.PMID:34909804 | DOI:10.1358/dot.2021.57.12.3393255 (Source: Drugs of Today)
Source: Drugs of Today - December 15, 2021 Category: Drugs & Pharmacology Authors: M Spence Source Type: research